资金流向方面，今日主力资金净流出4095.19万元，占比成交额12.15%。其中，超大单净流出1606.36万 元、占成交额4.77%，大单净流出2488.83万元、占成交额7.38%，中单净流出流出1186.35万元、占成交 额3.52%，小单净流入5281.54万元、占成交额15.67%。 三博脑科最新一期业绩显示，截至2025一季报，公司营业总收入3.93亿元、同比增长16.78%，归属净利 润3831.36万元，同比增长14.56%，扣非净利润3860.63万元，同比增长19.40%，流动比率1.879、速动比 率1.767、资产负债率25.59%。 天眼查商业履历信息显示，三博脑科医院管理集团股份有限公司，成立于2003年，位于北京市，是一家 以从事卫生为主的企业。企业注册资本20598.6987万人民币，实缴资本20598.6987万人民币。公司法定 代表人为张阳。 通过天眼查大数据分析，三博脑科医院管理集团股份有限公司共对外投资了12家企业，参与招投标项目 2次，知识产权方面有商标信息33条，此外企业还拥有行政许可3个。 来源：金融界 金融界消息 截至2025年7月29日收盘，三博脑科（3012 ...

Group 1 - The Beijing Future Science City Management Committee has developed a draft implementation plan for the "Artificial Intelligence + Pharmaceutical Health" industry in Changping District, focusing on brain-computer interface (BCI) innovation [1] - The plan emphasizes the development and application of BCI products, supporting research in key areas such as neural signal acquisition, decoding, control, and feedback [1] - The document encourages medical and health institutions in the region to adopt BCI products for clinical applications in treating neurological and mental disorders, as well as in smart rehabilitation and health monitoring [1] Group 2 - Open Source Securities highlights the significant potential of the downstream application market for brain-computer interfaces, which connect the brain with external devices for information exchange [2] - The BCI technology is expected to accelerate its implementation due to favorable policies and technological advancements, benefiting companies such as Rock Mountain Technology, Zhongke Information, and others [2] - The applications of BCI span across medical fields for disease warning, diagnosis, treatment, and functional enhancement, as well as in consumer and industrial sectors [2]

从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均48.04倍，行业中值58.89倍，三博脑科排 名第37位。 最新一期业绩显示，2025年一季报，公司实现营业收入3.93亿元，同比16.78%；净利润3831.36万元， 同比14.56%，销售毛利率26.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三博脑科91.7195.964.31100.79亿行业平均 48.0458.954.14194.93亿行业中值58.8965.713.2364.41亿1药明康德23.5427.854.392631.53亿2康龙化成 29.3530.583.91548.40亿3爱尔眼科32.8334.225.571216.96亿4诺禾致源33.3234.432.6867.76亿5普蕊斯 36.4831.242.8233.25亿6诺思格37.2138.012.8653.30亿7通策医疗40.1340.994.88205.53亿8华厦眼科 40.4739.882.90170.94亿9华康洁净40.4742.361.6328.30亿10凯莱英42.8344.852.48425.57亿11万邦医药 46.613 ...

Core Viewpoint - The A-share market faced a significant shock on July 25, with the China Securities Regulatory Commission (CSRC) issuing five investigation orders against listed companies, leading to substantial losses for 168,600 retail investors [1] Group 1: Company-Specific Issues - Rebecca, known as the "wig king," had a market value of 4.2 billion yuan and concealed related party fund occupation for four consecutive years, resulting in a loss of 117 million yuan in 2024 that was not disclosed [1] - ST Wanfang experienced a dramatic "performance reversal," initially forecasting a profit of 20 million yuan in January but later reporting a loss of 5 million yuan in April, triggering delisting risk [2] - Sanfeng Intelligent faced internal control issues, with its director under "supervision" and significant vulnerabilities exposed, despite claims of normal operations [2] - Taiyuan Heavy Industry and ST Mubang are also under investigation, with Taiyuan's major shareholder proposing an 80 million yuan buyback plan to stabilize stock prices [4] Group 2: Regulatory Environment - The CSRC is intensifying efforts to combat violations in the capital market, with new regulations increasing penalties for information disclosure violations, including fines up to 10 million yuan for individuals [6] - The medical industry has become a focal point for regulatory scrutiny, with numerous companies being investigated for corruption related to "kickback sales" [6] Group 3: Investor Lessons - Stocks under investigation have seen significant price declines, with ST Dongtong's stock price halving after being investigated, resulting in average losses exceeding 100,000 yuan for 70,000 shareholders [5] - Investors are advised to recognize high-risk signals, such as investing in ST companies or those with a history of warnings, as exemplified by Rebecca's failure to rectify issues after receiving multiple warnings [7] - Caution is advised regarding shareholder structure, particularly in stocks with low institutional holdings or high trust pledge rates, as seen with ST Wanfang [7] - Investors should consider selling stocks immediately upon news of investigations, as the likelihood of rebounds for such stocks is less than 20% [7]

Core Insights - The global brain-computer interface (BCI) industry is experiencing significant advancements, with companies like Neuralink successfully completing dual surgeries in one day [1] - China is emerging as a vibrant market for BCI technology, with various cities implementing industry cultivation plans to accelerate the transition from laboratory to commercialization [1][2] Industry Developments - The Beijing Brain Science and Brain-like Research Institute has completed the world's first flexible high-throughput semi-invasive wireless implanted BCI system, achieving over 98% effective channel count [2] - China has entered the clinical trial phase for invasive BCI technology, becoming the second country globally to do so [2] - The BCI technology in China is transitioning from early functional validation to large-scale application, marking a critical period for commercialization [2] Regional Initiatives - Nanjing has launched an action plan aiming to establish itself as a research and transformation hub for BCI by 2027 and a national innovation leader by 2030 [3] - Shanghai has initiated the "Brain Intelligence World" project, integrating clinical resources and research platforms to foster BCI innovation [3] - Beijing's action plan aims to form a BCI industry ecosystem by 2030, with goals to cultivate influential tech enterprises and establish demonstration zones for BCI applications [4] Market Potential - A report by CCID Consulting predicts that China's BCI market will reach 5.58 billion yuan by 2027 [5] - Companies are increasing R&D investments across the entire BCI supply chain, including chips, sensors, and algorithms, contributing to the industry's rapid development [5][6] Innovation and Collaboration - Several A-share listed companies are enhancing their R&D capabilities, with a focus on both invasive and non-invasive BCI strategies [6] - The domestic BCI industry is shifting from a "follower" to a "parallel runner" model, achieving greater autonomy in core technology [6] - Collaborative efforts among universities, hospitals, and enterprises are driving innovation and expanding application scenarios for BCI technology [6]

Core Viewpoint - Several companies have announced significant investments, acquisitions, and strategic partnerships, indicating a trend of expansion and diversification in various sectors, including technology, energy, and manufacturing [3][4][15][26]. Group 1: Investments and Acquisitions - Guizhou Moutai plans to establish a research institute with its controlling shareholder, contributing a total of 10 billion yuan in registered capital, with Moutai contributing 4.9 billion yuan for a 49% stake [3]. - GoerTek intends to acquire 100% of Hong Kong Mia and Changhong Limited for approximately 104 billion HKD (around 95 billion yuan), enhancing its capabilities in precision metal components [4][5]. - China Nuclear Power is set to invest 1 billion yuan in China Fusion Energy Company, aiming to strategically position itself in the nuclear fusion energy sector [15]. - Hunan YN plans to invest approximately 9.5 billion yuan in a lithium battery cathode material project in Malaysia, enhancing its market presence in Southeast Asia [16]. - Tianrun Industrial proposes to acquire 100% of Shandong Altai for 135 million yuan, focusing on automotive lightweight components [18]. - Kema Technology aims to purchase 73% of Suzhou Kaixin Semiconductor for 102 million yuan, expanding its product offerings in silicon carbide materials [24]. Group 2: Project Developments - Sichuan Chengyu is part of a consortium that has been pre-selected for the G5 Jingkun Expressway expansion project, with an estimated total investment of 285.48 billion yuan, where the company plans to contribute approximately 49.02 billion yuan [8]. - Zhejiang Fu Holdings' subsidiary is involved in the research and development of large-scale hydropower generator sets, with a focus on the Yarlung Tsangpo River downstream hydropower project [6]. Group 3: Financial Performance - Anfu Technology reported a net profit of 107 million yuan for the first half of 2025, marking a 14.38% increase year-on-year, driven by overseas alkaline battery business expansion [26]. - Jieput's net profit is expected to increase by 57.03% to 82.6% in the first half of 2025, benefiting from rising global laser demand [27]. - Microelectrophysiology anticipates a net profit increase of 76.34% to 105.73% for the same period, attributed to successful product launches in the cardiac electrophysiology field [29]. - Jiangling Motors reported a net profit of 733 million yuan for the first half of 2025, a decline of 18.17% year-on-year, despite a slight revenue increase [30].

Group 1 - Guizhou Moutai plans to establish a research institute company with its controlling shareholder, Moutai Group, with a registered capital of 1 billion yuan, where Guizhou Moutai will contribute 490 million yuan for a 49% stake [3] - Zhejiang Fu Holdings' subsidiary focuses on the research, design, manufacturing, and service of large and medium-sized hydropower turbine generator sets, with a significant project in the Yarlung Zangbo River area currently in the early construction phase [4] - Geer Software intends to acquire over 51% of Shenzhen Weipin Zhiyuan Information Technology Co., a leading digital transformation service provider in China [5] Group 2 - Sichuan Chengyu is part of a consortium that is the first candidate for the G5 Jingkun Expressway expansion project, with an estimated total investment of approximately 28.55 billion yuan, and the company plans to invest 4.902 billion yuan [6] - Sichuan Road and Bridge's subsidiary is participating in the same G5 Jingkun Expressway project, holding a 4% stake, with a total project investment of 28.55 billion yuan [7] - Xining Special Steel confirmed that there are no undisclosed significant information after its stock price experienced unusual fluctuations [8] Group 3 - Sanbo Brain Science's chairman has had his detention lifted and is now under investigation, returning to work [9][10] - Anke Intelligent Electric reported no significant changes in its operating environment and plans to disclose its semi-annual report on August 26 [11] - Funeng Technology received a development notice from GAC Group for battery supply, indicating increased market recognition for its SPS battery products [12] Group 4 - China Nuclear Power plans to invest 1 billion yuan in China Fusion Energy Company, acquiring a 6.65% stake, as part of a forward-looking strategy in the nuclear fusion energy sector [13] - Anfu Technology reported a net profit of 107 million yuan for the first half of 2025, a year-on-year increase of 14.38% [15] - Jieput's net profit is expected to increase by 57.03% to 82.6% in the first half of 2025, driven by rising demand for laser devices [16] Group 5 - Microelectrophysiology anticipates a net profit increase of 76.34% to 105.73% in the first half of 2025, supported by strong overseas sales of its heart electrophysiology products [17] - Zhongman Petroleum signed a gas exploration and development contract in Algeria, with a 90% investment share in the Zerafa II block, which has an estimated gas resource of 109.257 billion cubic meters [20] - Guizhou Gas shareholders plan to reduce their holdings by up to 6% through various trading methods [22]

三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日披露了《关于控股股东、实际控制人之一暨董事长被留置和立案调查的公 告》（公告编号：2025-022），公司控股股东、实际控制人之一暨董事长张阳先 生被实施留置、立案调查。 现公司收到内蒙古自治区监察委员会签发的《变更留置通知书》，内蒙古自 治区监察委员会已解除对张阳先生的留置措施，变更为责令候查措施。目前，张 阳先生已回到工作岗位正常履职。 证券代码：301293 证券简称：三博脑科 公告编号：2025-027 三博脑科医院管理集团股份有限公司 关于控股股东、实际控制人之一暨董事长解除留置并变更为 责令候查的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司将持续关注上述事项的后续进展情况，并严格按照相关规定及时履行信 息披露义务。公司指定的信息披露媒体为《证券时报》《证券日报》《中国证券 报》《上海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn），公司 发布的信息均以在上述指定媒体刊登的信息为准。敬请广大投资者理性投资，注 意投资风险。 三博 ...

Summary of Key Points from Conference Call Records Industry or Company Involved - **Semiconductor Packaging Industry**: Focus on TSMC's CoWoS technology and related companies - **RISC-V Architecture**: Development and adoption in high-performance computing - **Micro-Short Drama Industry**: Growth and government support in Shenzhen - **Brain-Computer Interface (BCI) Technology**: Medical applications and market potential - **AI in Healthcare**: Investment trends and technological advancements - **Tourism and Cruise Industry**: Summer tourism trends and company initiatives - **Robotics and AI**: Development in military and healthcare applications Core Insights and Arguments Semiconductor Packaging - TSMC is advancing its CoWoS technology, with expected Q3 sales between $31.8 billion and $33.1 billion, exceeding market estimates [2][3] - The global market for CoWoS technology is projected to exceed $10 billion by 2026, with China leading growth at 71% [2] RISC-V Architecture - The fifth RISC-V China Summit highlighted the acceleration of high-performance computing products [4] - Companies like Aojie Technology and Allwinner Technology are leading in RISC-V CPU subsystem development [5] Micro-Short Drama - Shenzhen's government has introduced measures to support the micro-short drama industry, with a market size expected to reach 68.6 billion yuan in 2025, growing at 36% [6][7] Brain-Computer Interface - The global BCI medical application market is projected to reach $40 billion by 2030, with significant growth in central nervous system disease treatments [8] - Companies like Yanshan Technology and Sanbo Brain Science are pioneering BCI applications [9] AI in Healthcare - The global AI healthcare investment landscape is heating up, with significant advancements in molecular modeling technology [11] - The company is collaborating with Tencent AI Lab to enhance drug discovery processes [11] Tourism and Cruise - The domestic summer tourism consumption is expected to reach 1.8 trillion yuan, with the company launching themed cruise lines [13] Robotics and AI - The military robotics sector is accelerating, with new developments in multifunctional robots for reconnaissance and inspection [16] - Companies are also focusing on healthcare robotics, with applications in rehabilitation and elderly care [15] Other Important but Potentially Overlooked Content - The CoWoS technology's capacity is directly linked to HBM production, indicating a critical supply chain relationship [2] - The RISC-V architecture's integration into data centers could disrupt traditional CPU markets [4] - The micro-short drama market's growth is driven by free content, highlighting a shift in consumer preferences [6] - The BCI technology's commercialization is supported by new pricing regulations in Hubei province [8] - The AI healthcare sector is seeing a convergence of technology and traditional pharmaceutical practices, enhancing drug development efficiency [11] - The cruise tourism initiative is part of a broader strategy to diversify offerings in response to changing consumer demands [13] - The military robotics market is expected to see increased government investment and interest, particularly in AI applications [16]

证券代码：301293 证券简称：三博脑科 公告编号：2025-026 | | | | | | | 占剔除公司回 | | --- | --- | --- | --- | --- | --- | --- | | 股东 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 占公司目前 | 购专用账户股 | | 名称 | | | （元） | （股） | 总股本比例 | 份数量后总股 | | | | | | | | 本的比例 | | TBP | 集中竞价 | 2025.4.18-2025.7.11 | 45.21 | 1,124,600 | 0.546% | 0.554% | 1、股东减持股份情况 三博脑科医院管理集团股份有限公司 关于持股 5%以上股东减持股份计划期间届满暨实施情况的公告 公司股东 TBP 3Doctors (HK) Limited 保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 三博脑科医院管理集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日披露了《关于持股 5%以上 ...